Key result
PLA2G7 V379 allele is linked to a lower risk of future cardiovascular events.
Why the study?
PAF-AH activity has been postulated as a risk factor for CAD, but its causal role versus marker status remains unclear.
Does the PLA2G7/A379V polymorphism reduce the risk of future cardiovascular events in patients with coronary artery disease?
Cohort (n=1,799)
Does the PLA2G7/A379V polymorphism reduce the risk of future cardiovascular events in patients with coronary artery disease?
The V379 allele of the PLA2G7 gene may confer a protective effect against the development of coronary artery disease and subsequent cardiovascular events.
Answers are grounded in this paper and cite their sources.
PLA2G7 V379 may mark lower CAD risk; leaves open whether PAF-AH activity modulates events or remains a noncausal marker.
Oxidation of low density lipoproteins is an initial step of atherogenesis that generates pro-inflammatory phospholipids, including platelet-activating factor (PAF) and its analogs. PAF is degraded by PAF-acetylhydrolase (PAF-AH), a circulating enzyme having both pro- and anti-inflammatory activities. PAF-AH activity has been postulated to be a risk factor for coronary artery disease (CAD); however, whether PAF-AH has a causal role or is simply a marker of risk is unclear. The aim of this study was to relate the variability of the genes encoding PAF-AH (PLA2G7) and the PAF-receptor (PTAFR) to the risk of CAD and its complications. All polymorphisms located in putatively functional regions were investigated in a prospective cohort of CAD patients (n = 1314) and a group of healthy controls (n = 485). The whole gene variability was investigated in relation to case-control status, prospective cardiovascular outcome and plasma PAF-AH levels by means of haplotype analyses. All analyses indicated an effect of the PLA2G7/A379V polymorphism independent of the other polymorphisms. The V379 allele was less frequent in CAD patients than in controls and was associated with a lower risk of future cardiovascular events, suggesting that this allele might be protective against the development of CAD. The V379 allele was also associated with a weak increase of plasma PAF-AH activity that was unlikely to explain the protective effect of the allele on risk. A more likely interpretation is that the A379V polymorphism might modify the enzyme function towards a more anti-atherogenic form. Polymorphisms of the PTAFR gene were not related to any phenotype.
No takes yet. Share an insight, caveat, or question.
Ewa Ninio (2004) conducted a cohort in Coronary artery disease (n=1,799). PLA2G7/A379V polymorphism (V379 allele) vs. Non-carriers / other alleles was evaluated on Risk of CAD and future cardiovascular events. The V379 allele of the PLA2G7 gene was less frequent in CAD patients than controls and was associated with a lower risk of future cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: